Innovent Biologics Inc (6IB) - Net Assets
Based on the latest financial reports, Innovent Biologics Inc (6IB) has net assets worth €19.36 Billion EUR (≈ $22.63 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€37.35 Billion ≈ $43.66 Billion USD) and total liabilities (€17.99 Billion ≈ $21.03 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Innovent Biologics Inc total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.36 Billion |
| % of Total Assets | 51.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | 87.37% |
| 10-Year Change | N/A |
| Growth Volatility | 27.12 |
Innovent Biologics Inc - Net Assets Trend (2016–2025)
This chart illustrates how Innovent Biologics Inc's net assets have evolved over time, based on quarterly financial data. Check 6IB goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Innovent Biologics Inc (2016–2025)
The table below shows the annual net assets of Innovent Biologics Inc from 2016 to 2025. For live valuation and market cap data, see how much is Innovent Biologics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €19.36 Billion ≈ $22.63 Billion |
+47.56% |
| 2024-12-31 | €13.12 Billion ≈ $15.34 Billion |
+4.71% |
| 2023-12-31 | €12.53 Billion ≈ $14.65 Billion |
+16.75% |
| 2022-12-31 | €10.73 Billion ≈ $12.54 Billion |
+3.87% |
| 2021-12-31 | €10.33 Billion ≈ $12.08 Billion |
+17.66% |
| 2020-12-31 | €8.78 Billion ≈ $10.26 Billion |
+84.60% |
| 2019-12-31 | €4.76 Billion ≈ $5.56 Billion |
+13.39% |
| 2018-12-31 | €4.19 Billion ≈ $4.90 Billion |
+358.57% |
| 2017-12-31 | €-1.62 Billion ≈ $-1.90 Billion |
-69.29% |
| 2016-12-31 | €-958.22 Million ≈ $-1.12 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Innovent Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1416299500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €34.45 Billion | 177.97% |
| Total Equity | €19.36 Billion | 100.00% |
Innovent Biologics Inc Competitors by Market Cap
The table below lists competitors of Innovent Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wipro Limited
F:WIOA
|
$16.77 Billion |
|
Sinopac Financial Holdings Co Ltd
TW:2890
|
$16.78 Billion |
|
NVR Inc
NYSE:NVR
|
$16.80 Billion |
|
CF Industries Holdings Inc
NYSE:CF
|
$16.81 Billion |
|
Computershare Ltd
AU:CPU
|
$16.75 Billion |
|
JSC National Atomic Company Kazatomprom
IL:KAP
|
$16.75 Billion |
|
Ovintiv Inc
NYSE:OVV
|
$16.74 Billion |
|
WESCO International Inc
NYSE:WCC
|
$16.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovent Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,117,729,000 to 19,356,243,000, a change of 6,238,514,000 (47.6%).
- Net income of 813,565,000 contributed positively to equity growth.
- New share issuances of 4,718,755,000 increased equity.
- Other factors increased equity by 706,194,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €813.57 Million | +4.2% |
| Share Issuances | €4.72 Billion | +24.38% |
| Other Changes | €706.19 Million | +3.65% |
| Total Change | €- | 47.56% |
Book Value vs Market Value Analysis
This analysis compares Innovent Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-1.74 | €9.47 | x |
| 2018-12-31 | €3.64 | €9.47 | x |
| 2019-12-31 | €3.77 | €9.47 | x |
| 2020-12-31 | €6.26 | €9.47 | x |
| 2021-12-31 | €7.07 | €9.47 | x |
| 2022-12-31 | €6.99 | €9.47 | x |
| 2023-12-31 | €7.72 | €9.47 | x |
| 2024-12-31 | €8.01 | €9.47 | x |
| 2025-12-31 | €11.16 | €9.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovent Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.24%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.93x
- Recent ROE (4.20%) is above the historical average (-24.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | €-365.81 Million |
| 2017 | 0.00% | -3033.33% | 0.01x | 0.00x | €-368.06 Million |
| 2018 | -137.60% | -60899.99% | 0.00x | 1.46x | €-6.19 Billion |
| 2019 | -36.16% | -164.19% | 0.14x | 1.52x | €-2.20 Billion |
| 2020 | -11.37% | -25.97% | 0.32x | 1.35x | €-1.88 Billion |
| 2021 | -30.38% | -73.50% | 0.26x | 1.57x | €-4.17 Billion |
| 2022 | -20.31% | -47.83% | 0.26x | 1.64x | €-3.25 Billion |
| 2023 | -8.21% | -16.56% | 0.30x | 1.65x | €-2.28 Billion |
| 2024 | -0.72% | -1.00% | 0.44x | 1.65x | €-1.41 Billion |
| 2025 | 4.20% | 6.24% | 0.35x | 1.93x | €-1.12 Billion |
Industry Comparison
This section compares Innovent Biologics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,387,018,495
- Average return on equity (ROE) among peers: -76.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovent Biologics Inc (6IB) | €19.36 Billion | 0.00% | 0.93x | $16.76 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $186.58 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.06 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $20.06 Billion | 47.04% | 0.16x | $20.05 Billion |
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more